

Pregnancy in Women with Non-classic Congenital Adrenal Hyperplasia: Time to Conceive and Outcome

Ori Eyal, Irit Ayalon, Anat Segev-Becker, Anita Schachter-Davidov, Asaf Oren, Naomi Wentrob

Pediatric Endocrinology and Diabetes Unit, Dana-Dwek Children Hospital, Tel Aviv
Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv.

Background

- Non-classic Congenital Adrenal Hyperplasia (NC21OHD) is very common (1:400) in Ashkenazi Jews
- Genotype: homozygous or compound heterozygous
- Therapy with small dose of glucocorticoids (GC) to symptomatic subjects
- Others reported increased rate of miscarriages in non treated NC21OHD
- Time to conceive was not compared between treated and untreated females

Aims

- To assess time to conceive and pregnancy outcome according to glucocorticoid (GC) treatment in women with NC21OHD
- To assess the impact of age at diagnosis, genotype, androgens levels, Polycystic Ovary (PCO) and Body Mass Index (BMI) on pregnancy outcome


Methods

- Retrospective observational study in a tertiary medical center
- Data extraction from files of NC21OHD women who wished pregnancy
- The study was approved by the local ethics committee


Demographic Data

- Fifty nine women
- Age at study [Median (range)] - 36 years (21-59)
- Age at diagnosis [Median (range)] - 20 years (0.1-38)
- Age (mean \pm sd) at pubarche- 9.6 \pm 2.8 yr was younger than age at gonadarche, 11.0 \pm 2.0 yr ($p < 0.001$)
- PCO prevalence 28.6%

Ethnic origin




Genotype



Results

Outcomes of Pregnancies by GC Therapy



| Pregnancy outcome | Pregnancies without GC treatment (n=29) | Pregnancies with GC treatment (n=101) | p |
|---------------------------|---|---------------------------------------|------|
| Time to conceive (months) | 15.1 \pm 37.7 | 6.9 \pm 8.5 | 0.01 |
| Outcome | | | |
| Miscarriages | 5 (17.2%) | 25 (24%) | NS |
| Live births | 24 (82.8%) | 76 (76%) | NS |
| Birth weight (Kg) | 3.2 \pm 0.5 | 3.0 \pm 0.5 | 0.03 |
| Week delivery | 38.7 \pm 2.7 | 38.7 \pm 1.7 | 1.0 |

- Hydrocortisone equivalent (HC) dose: First trimester 7.2 \pm 3.4 mg/m² > second and third trimester (6.5 \pm 3.0 and 6.7 \pm 3.7 mg/m², respectively, $p < 0.001$)
- Treatment was stopped in 14% of pregnancies due to normal androgen levels for pregnancy

Pregnancy Outcome By PCO

| Outcome | PCO | Non PCO | p |
|-------------|------------|------------|-------|
| Live birth | 20 (57.1%) | 59 (76.6%) | 0.054 |
| Miscarriage | 15 (42.9%) | 18 (23.4%) | |

- Treated women with PCO had significant longer time to conceive compared to women without PCO (4.1 \pm 6.1 vs. 8.7 \pm 7.6 months, $p = 0.001$)
- There was no impact of age at diagnosis, BMI, 17OHP and androgen levels on time to conceive and pregnancy outcome
- 24% of the newborns had NC21OHD
- 1% of the newborns had classic CAH

Discussion

- GC therapy significantly shortened the time to conceive in females with NC21OHD
- No significant difference in miscarriages rate among treated and untreated pregnancies
- The incidence of NC21OHD was five fold and of classical CAH two fold higher than expected

